Aripiprazole Tablet
Product Images NDC 71335-1892

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 71335-1892). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Figure1)

A chart titled 'Effect of Other Drugs on Aripiprazole' illustrating the fold change and 90% confidence intervals in pharmacokinetic parameters AUC and Cmax of Aripiprazole when co-administered with various drugs including ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, and lorazepam. The horizontal axis shows change relative to reference without interacting drug, ranging from 0.0 to 3.0.*

FDA Label Image

Figure2 (Figure2)

A pharmacokinetic chart titled 'Effect of Other Drugs on Aripiprazole' showing fold change and 90% confidence intervals in dehydro-aripiprazole levels relative to reference without interacting drug. The x-axis represents change relative to reference (0.0 to 3.0), and the y-axis lists interacting drugs, including CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and others (valproate, lithium, lorazepam). Vertical markers indicate fold change in AUC and Cmax for each interacting drug.*

FDA Label Image

Figure3 (Figure3)

A forest plot chart titled 'Effect of Aripiprazole on Other Drugs' showing fold change and 90% confidence intervals for various drugs' pharmacokinetic parameters (AUC, Cmax, DMWRP, INR) relative to reference values without interacting drugs. Drugs listed include dextromethorphan, S- and R-warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, and O-desmethylvenlafaxine, with fold changes plotted along an x-axis from 0.0 to 3.0.*

FDA Label Image

Figure4 (Figure4)

A chart titled 'Aripiprazole Fold Change and 90% CI' depicting pharmacokinetic fold changes and confidence intervals for Aripiprazole in special populations. It compares variables such as CYP2D6 metabolizer status, gender, age groups, and levels of hepatic and renal impairment against reference values for AUC and Cmax, showing changes relative to reference on the x-axis.*

FDA Label Image

Figure5 (Figure5)

A pharmacokinetic (PK) graph showing the fold change and 90% confidence interval (CI) of dehydro-aripiprazole relative to a reference. The horizontal axis represents change relative to reference, and the vertical axis lists factors such as CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment. Data points illustrate differences in AUC and Cmax values between comparison groups.*

FDA Label Image

Structure (Structure)

Chemical structure diagram of aripiprazole, showing the arrangement of atoms and chemical bonds characteristic of this active pharmaceutical ingredient.*

FDA Label Image

Camberlogo (Camber Logo)

FDA Label Image

Figure 6 (Figure 6)

A line graph showing the proportion with relapse over days from randomization, comparing Aripiprazole and placebo groups. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. Two lines represent the groups: a solid line for Aripiprazole and a dashed line for placebo. Below the x-axis, a table displays the number of subjects at risk over time for each group.*

FDA Label Image

Figure 7 (Figure 7)

A Kaplan-Meier survival curve chart showing the proportion with relapse over days from randomization for Aripiprazole versus placebo. The x-axis represents days from randomization up to 182 days, and the y-axis shows the proportion with relapse from 0 to 1. Lines compare Aripiprazole (solid line) and placebo (dashed line). Below the x-axis is a table indicating the number of subjects at risk over time for each group.*

FDA Label Image

Figure 8 (Figure 8)

A Kaplan-Meier curve comparing the proportion of relapse over time between Aripiprazole and placebo groups in a clinical study. The x-axis shows days from randomization up to 364 days, while the y-axis represents the proportion with relapse from 0 to 1. Numbers of subjects at risk are listed below the x-axis for each group.*

FDA Label Image

Label (Lbl713351892)

Aripiprazole 2 mg tablet label by Bryant Ranch Prepack. The label shows the product name, strength, dosage form, and a note to compare to Abilify 2 mg tablet from Hetero Labs Limited. It includes storage instructions at 20°-25°C (68°-77°F), a warning to keep drugs out of children's reach, the lot number 1523487, an NDC of 71335-1892-1, and a barcode. The packaging is for 30 tablets and is prescription only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.